CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Malaysia
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData, the industry analysis specialist, has released its latest report: “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Malaysia”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Malaysia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts. In 2015, Malaysia’s population stood at 31 million. The past five years have seen steady population growth, which is expected to continue in the future due to a high birth rate, low mortality rate and increased life expectancy. Government initiatives such as Entry Point Projects (EPPs), specifically EPP3, and National Key Economic Areas (NKEAs) to increase investment in the pharmaceutical industry have so far have been successful. The country’s pharmaceutical market was estimated at $2.3 billion in 2015 and is projected to reach approximately $3.6 billion by 2020 at a CAGR of 9.5%. The medical device market was worth an estimated $1.7 billion in 2015, but is growing and currently constitutes approximately 25% of the healthcare expenditure. These positive trends can primarily be attributed to: An increasing elderly population Government initiatives to improve healthcare facilities An increase in medical tourism
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Malaysia, and includes:
An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
Profiles and SWOT analyses of the major players in the pharmaceutical market: Pharmaniaga Berhad, Chemical Company of Malaysia Berhad (CCM), Yung Shin Pharmaceutical, Hovid and Kotra Pharma
Insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
An overview of the opportunities for and challenges to growth in the Malaysian healthcare market
Reasons to Buy
This report will enhance your decision-making capability by allowing you to:
Develop business strategies by understanding the trends shaping and driving Malaysia’s healthcare market
Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
Identify, understand, and capitalize on the opportunities and challenges in Malaysia’s healthcare market
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.